Dyssynergia phenotypes in obstructed defecation: insights from Fecobionics assessment
Wenbo Li1, Mingyang Hou2, Yi Li1
1Department of Gastroenterology, Army Medical University Daping Hospital, Chongqing, China.
Objective:
Obstructed defecation syndrome (ODS) is a chronic constipation subtype. Conventional tests are limited by non-physiological conditions and poor correlation with symptoms. This study investigated anorectal dynamics and dyssynergia phenotypes in patients with ODS using Fecobionics.
Methods:
This study was designed as a prospective observational study including 10 control subjects and 25 patients with ODS. All measurements were performed according to a predefined protocol. All patients with ODS underwent clinical evaluation, anorectal manometry (ARM) and defecography. Fecobionics recorded anorectal pressures, sensation and expulsion performance. Expulsion dynamics were further analysed using preload-afterload diagrams to characterise dyssynergia subtypes.
Results:
Compared with the control group, the ODS group showed prolonged expulsion time (76 (23-120) vs 18.7 s (10.6-34), p<0.01), reduced effective propulsive force (P_delta) (26.2 (8.6-35.9) vs. 48.2 cmH₂O (32.5-88.0), p<0.01), increased number of contractions (7 (4-14) vs 2.5 (1.3-3.8), p<0.01) and higher paradoxical contraction rates (71% (50-100) vs 0% (0-44), p<0.01). ARM during attempted evacuation (push) demonstrated lower anal relaxation rates in the ODS group (16% (12-37) vs 36% (27-44), p<0.03). Correlation analyses demonstrated that impaired Fecobionics metrics were associated with greater symptom burden. Three dyssynergia phenotypes were identified: multiple simultaneous contractions, insufficient or delayed anal relaxation and persistently elevated outlet pressure.
Conclusion:
Fecobionics enables integrated and physiologically relevant assessment of anorectal function and identifies distinct dyssynergia phenotypes in ODS, reflecting heterogeneous mechanisms of outlet obstruction with implications for individualised management.
Study Registration:
ChiCTR2300078807.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Assessment of the Rectum and Anus
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists


